A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Public ClinicalTrials.gov record NCT06265727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.
Study identification
- NCT ID
- NCT06265727
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 348 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2024
- Primary completion
- Jan 15, 2027
- Completion
- Jan 26, 2027
- Last update posted
- Jan 7, 2026
2024 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| City of Hope Cancer Center | Duarte | California | 91010 | Recruiting |
| Moores Cancer Centre at UC San Diego Health | San Diego | California | 92037 | Recruiting |
| Helen Diller Family Comprehensive Cancer Center - UCSF | San Francisco | California | 94115 | Recruiting |
| Rocky Mountain Cancer Centres | Denver | Colorado | 80218 | Active, not recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06510 | Recruiting |
| Florida Cancer Specialists | Orlando | Florida | 32806 | Recruiting |
| University of Chicago | Chicago | Illinois | 60637 | Recruiting |
| Hope and Healing Cancer Center | Hinsdale | Illinois | 60521 | Active, not recruiting |
| Dana-Faber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Nebraska Hematology Oncology | Lincoln | Nebraska | 68506 | Active, not recruiting |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | Active, not recruiting |
| Texas Oncology | Tyler | Texas | 75702 | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Active, not recruiting |
| Fred Hutchinson Cancer Center at University of Washington | Seattle | Washington | 98195 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06265727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 7, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06265727 live on ClinicalTrials.gov.